EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)

Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer

Longitudinales Remodeling der Tumor-Immun-Mikroumgebung unter Regorafenib, Nivolumab und Chemotherapie beim fortgeschrittenen Magenkarzinom

Kota Itahashi iD, Akihito Kawazoe, Tadayoshi Hashimoto iD, Yue Yan iD, Takuma Irie iD, Hiromi Ono, Hitomi Tamura iD, Kyoko Hongo iD, Takashi Ikeno iD, Masashi Wakabayashi, Akihiro Sato iD, Yoshiaki Nakamura iD und 9 weitere

Science Translational Medicine · 04.11.2026 · 18 (874)

DOI: 10.1126/scitranslmed.aec7235 ↗

Auf einen Blick

In einer Phase-1b/2-Studie bei 30 Patient:innen mit mismatch repair-proficientem Magenkarzinom zeigte die Erstlinientherapie mit Regorafenib, Nivolumab und Chemotherapie ein objektives Ansprechen bei 22 von 30 Patient:innen (73 %).

Fragestellung

Wie verändert die Erstlinientherapie mit Regorafenib, Nivolumab und Chemotherapie das Tumormikromilieu beim fortgeschrittenen Magenkarzinom?

Methode

Phase-1b/2-Studie (NCT05394740) bei 30 Patient:innen; Single-cell-RNA- und T-Zell-Rezeptor-Sequenzierung von Biopsien zu Baseline, unter Therapie und bei Progression.

Ergebnisse

22 von 30 Patient:innen zeigten ein objektives Tumoransprechen (73 %; 80 %-KI 60,3 bis 83,8). Unter Therapie nahmen tumorantigenreaktive CD8+-T-Zellen und M1-ähnliche Makrophagen zu; mehrere immunsuppressive Populationen nahmen ab.

Schlussfolgerung der Autor:innen

Die Autor:innen sehen ein dynamisches Remodeling der Tumormikroumgebung und potenzielle therapeutische Zielstrukturen.

Kernaussagen

  • Objektives Ansprechen bei 22 von 30 Patient:innen
  • Zunahme von CD8+-T-Zellen und M1-ähnlichen Makrophagen
  • Abnahme mehrerer immunsuppressiver Zellpopulationen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Science Translational Medicine, erschienen am 04.11.2026. Verfasst von Kota Itahashi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Pyridines, Stomach Neoplasms, Phenylurea Compounds. Die Arbeit nennt 78 Literaturangaben. Gefördert von: Bayer.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous studies combining the multikinase inhibitor regorafenib with a PD-1 inhibitor showed promising activity in gastric cancer. We conducted a phase 1b/2 trial (NCT05394740) of first-line regorafenib, nivolumab, and chemotherapy in 30 patients with mismatch repair–proficient gastric cancer and investigated its impact on the tumor microenvironment. The primary end point was met; 22 of 30 patients showed objective tumor response (73%; 80% confidence interval, 60.3 to 83.8). Single-cell RNA and T cell receptor sequencing were performed on biopsy samples at baseline, during treatment, and at disease progression. The combination treatment increased tumor antigen–reactive CD8 + T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8 + regulatory T cells, LRRC15 + cancer-associated fibroblasts (CAFs), RGS5 + pericytes, and APLN + tip cells. At progression, LRRC15 + CAFs and APLN + tip cells remained reduced, activated CCR8 + regulatory T cells reexpanded, and additional treatment-resistant subsets emerged, including APOC1 + lipid-associated macrophages. In murine models of acquired resistance, therapeutic targeting of these suppressive immune cell populations with antibodies against CCR8 or TREM2 in combination with PD-1 blockade restored antitumor immunity. These findings demonstrate dynamic remodeling of the tumor microenvironment and suggest potential therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentPyridinesStomach NeoplasmsPhenylurea CompoundsNivolumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAnimalsMaleMiddle AgedAgedMacrophagesMice

Substanzen

regorafenibPyridinesPhenylurea CompoundsNivolumab

Autor:innen und Institutionen

  • Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Kashiwa, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Laboratory of Computational Life Science, National Cancer Center Research Institute, Tokyo, Japan.
  • Department of Immunogenomic Medicine, Research Institute, National Cancer Center, Tokyo, Japan.

ORCID-Profile: Kota Itahashi, Tadayoshi Hashimoto, Yue Yan, Takuma Irie, Hitomi Tamura, Kyoko Hongo, Takashi Ikeno, Akihiro Sato, Yoshiaki Nakamura, Tomohiro Iwasawa, Tomoya Suzuki, Izuma Nakayama, Takayuki Yoshino, Hiroyoshi Nishikawa, Shohei Koyama, Kohei Shitara

Förderung

  • Bayer

Zitieren

APA

Itahashi, K., Kawazoe, A., Hashimoto, T., Yan, Y., Irie, T., Ono, H., Tamura, H., Hongo, K., Ikeno, T., Wakabayashi, M., Sato, A., Nakamura, Y., Fujisawa, T., Iwasawa, T., Suzuki, T., Nakayama, I., Kojima, Y., Yoshino, T., Nishikawa, H., …, & Shitara, K. (2026). Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer. Science Translational Medicine, 18(874). https://doi.org/10.1126/scitranslmed.aec7235

Vancouver

Itahashi K, Kawazoe A, Hashimoto T, Yan Y, Irie T, Ono H, et al. Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer. Science Translational Medicine. 2026;18(874). doi:10.1126/scitranslmed.aec7235

BibTeX
@article{Itahashi2026,
  author = {Itahashi, Kota and Kawazoe, Akihito and Hashimoto, Tadayoshi and Yan, Yue and Irie, Takuma and Ono, Hiromi and Tamura, Hitomi and Hongo, Kyoko and Ikeno, Takashi and Wakabayashi, Masashi and Sato, Akihiro and Nakamura, Yoshiaki and Fujisawa, Takao and Iwasawa, Tomohiro and Suzuki, Tomoya and Nakayama, Izuma and Kojima, Yasuhiro and Yoshino, Takayuki and Nishikawa, Hiroyoshi and Koyama, Shohei and Shitara, Kohei},
  title = {Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {874},
  doi = {10.1126/scitranslmed.aec7235}
}
Kostenlos starten →